Nancie Schildgen

FDA OKs First-Line Lazertinib With Amivantamab for NSCLC

August 20, 2024

The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for upfront treatment of...

Nancie Schildgen

FDA OKs First-Line Lazertinib With Amivantamab for NSCLC

Is This the Best Prostate Biopsy?

Cancer Risk: Are Pesticides the New Smoking?

Adalimumab Tops Cyclosporine in Preventing Uveitis Relapse

Five Steps to Improve Colonoscopy Performance

Triptans Trump Newer, More Expensive Meds for Acute Migraine

Cheeky diet soft drink getting you through the work day? Here’s what that may mean for your health

UK teenagers get two-thirds of their calories from ultra-processed foods—new study

Some have called this area a birthing ‘desert.’ A nurse midwife is working to change that

‘State of health care for women is in a fragile place’—Florida women are dying from preventable causes

First Impressions Count in Healthcare

Is This the Best Prostate Biopsy?

Cancer Risk: Are Pesticides the New Smoking?

Adalimumab Tops Cyclosporine in Preventing Uveitis Relapse

Five Steps to Improve Colonoscopy Performance

Triptans Trump Newer, More Expensive Meds for Acute Migraine

About PhaMed

Recent News

You may have missed

About PhaMed

Recent News

Categories